diabetes
Conditions
Interventions
One:Treatment of PEG-Loxenatide
Two:Insulin glargine
Sponsors
Chu Hsien-lMemorial Hospital of TianjinMedical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Definite diagnosis of type 2 diabetes (using the 1999 WHO diagnostic criteria). 2.Not previously treated with anti-diabetic medications, or if treated with metformin alone, the duration should be no less than 8 weeks, with HbA1C levels between 7% and 9.0%. Duration of diabetes is less than 10 years. 3.Age is greater than or equal to 18 years old and less than 70 years old. 4.Family history of type 2 diabetes-related cardiomyopathy. 5.BMI greater than or equal to 28kg/m². 6.Other treatments: including stable lipid-lowering, blood pressure management, antiplatelet therapy, etc., for a duration of at least 3 months. 7.Willing to participate in and cooperate with the study, and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Type 1 diabetes; 2.Currently using glucocorticoids and other medications affecting blood sugar, or screened within the last 3 months for the use of GLP-1 receptor agonists or DPP4 enzyme inhibitors; 3.Allergic to GLP-1 receptor agonists; 4.Experienced acute complications of diabetes in the last 2 months, such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, etc.; 5.History of compromised immune function or malignant tumors, family or personal history of type 2 multiple endocrine neoplasia (MEN2), familial medullary thyroid carcinoma (FMTC), or personal history of non-familial medullary thyroid carcinoma; calcitonin greater than or equal to 50ng/L; 6.History of acute or chronic pancreatitis; 7.Experienced acute myocardial infarction, cerebrovascular accident, or severe infection within the 6 months prior to enrollment; 8.Uncontrolled hypertension: systolic blood pressure greater than 180mmHg and/or diastolic blood pressure greater than 110mmHg; 9.Abnormal liver function, with ALT or AST levels exceeding three times the normal upper limit; 10.Previously undergone percutaneous coronary intervention; individuals with arterial aneurysms; patients with cardiac pacemakers, nerve stimulators, artificial metallic heart valves, etc.; those with intraocular metal foreign bodies, implanted inner ear devices, metal prosthetics, metal joints, or ferromagnetic foreign bodies within the body; 11.Pregnant or planning to become pregnant, women in lactation; 12.Epilepsy, claustrophobia, or patients unable to cooperate with magnetic resonance imaging (MRI); 13.History of mental illness or individuals not adhering to the study plan and unable to perform research tasks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Balanced Turbo Field Echo;Characteristics of myocardial tissue; | — |
Secondary
| Measure | Time frame |
|---|---|
| height;weight;blood pressure;heart rate;Liver function;kidney function;OGTT;HbA1c;blood lipids;UCG;ACR;uma;ROS;Hs-CRP; | — |
Countries
China
Contacts
Public ContactHongyan Liu
Chu Hsien-lMemorial Hospital of TianjinMedical University
Outcome results
None listed